FOXP3 and neoplasm: Despite the decreased-percentage of PD1 positive cells and Foxp3 positive cells in CD4+ and CD8+ T cells following treatment with EP1 or EP2 without pIL-12 (Figure 4C–F), tumor growth continued in EP1 and EP2 groups (Figure 1B).